Liposarcoma - 50 Studies Found
Withdrawn |
: Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma : Dedifferentiated Liposarcoma : 2009-09-01 : Drug: IPI-504 IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatmen |
Active, not recruiting |
: Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial : Advanced and / or Metastatic Liposarcoma : 2012-09-14 : Drug: Pazopanib Patients will receive oral pazopanib, 800mg once daily and treatment will continue until |
Recruiting |
: Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma :
: 2014-09-05 : Drug: Trabectedin Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discret |
Completed |
: A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma : Advanced Liposarcoma or Leiomyosarcoma : 2011-04-26 :
|
Recruiting |
: A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma :
|
Terminated |
: Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial : Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma : 2012-10-29 : Drug: plitidepsin |
Completed |
: PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma :
: 2010-09-24 : Drug: Palbociclib Treatment will consist of either: |
Recruiting |
: Study of Abemaciclib in Dedifferentiated Liposarcoma :
: 2016-07-25 : Drug: Abemaciclib Other Name: LY2835219 |
Active, not recruiting |
: A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma :
: 2015-10-06 : Drug: ribociclib Oral, 600 mg x 1 a day, duration - according to response |